Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01628120 · ClinicalTrials.gov registry record · Phase 3
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 170
- Enrollment target
NCT01628120 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 170 participants.
The verdict
NCT01628120, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 170 participants
- Enrollment target
Study Summary
To determine the long term safety in treatment-emergent adverse events (TEAEs) of SC administration of Epoetin Hospira for maintenance of target hemoglobin (Hgb) levels in patients treated for anemia associated with chronic renal failure and on hemodialysis.
Interventions
- BIOLOGICAL Epoetin Hospira
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2012-05-31 |
| Est. Completion | 2015-02-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01628120
The ClinicalTrials.gov registry entry for NCT01628120 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Epoetin Hospira is the first listed.
NCT01628120 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01628120 about?
NCT01628120 is a clinical study titled "A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin". To determine the long term safety in treatment-emergent adverse events (TEAEs) of SC administration of Epoetin Hospira for maintenance of target hemoglobin (Hgb) levels in patients treated for anemia associated with chronic renal failure and on hemodialysis.
What is the current status of trial NCT01628120?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 170 participants. The study started on 2012-05-31. Estimated completion is 2015-02-13.
What interventions are being tested in trial NCT01628120?
The interventions under investigation include: Epoetin Hospira (BIOLOGICAL).
Who is sponsoring clinical trial NCT01628120?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.